Linkage is now part of Thermo Fisher's transplant diagnostics business, One Lambda. Linkage's flagship product line is its real-time PCR technology, LinkSeq.
The FDA approved the real-time PCR-based test for use on the Cobas 6800 and 8800 systems to assess the response of transplant patients to treatments.
The technology uses Thermo Fisher Scientific microarrays to measure transcript levels in order to diagnose rejection of solid organ transplants.
The company also said it has closed a new $25 million debt facility, and will use the proceeds to retire outstanding debt and bolster the launch of AlloSure.
The algorithm identifies proteins in blood samples taken after bone marrow transplants that predict patients at risk for severe graft-versus-host disease.
The firm missed analyst estimates for revenues and loss per share, citing a continued investment in its AlloSure NGS test for the wider-than-expected loss.
CMDL is usingGenestack's platform to evaluate the effectiveness of bone marrow transplants and plans to use it for other oncology tests as well.
The companies are combining GMSbiotech's proprietary microarray platform with soluble human leukocyte antigen proteins produced by Pure Protein.
An analysis of samples taken a year after kidney transplant identified overlapping gene expression signatures associated with acute and chronic rejection.
Tricare is the healthcare program for active and returned military service members and their families, and covers more than 9 million individuals.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.